Point72 Asset Management L.P. Cuts Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Point72 Asset Management L.P. lessened its holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 25.2% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 360,732 shares of the company's stock after selling 121,598 shares during the period. Point72 Asset Management L.P. owned approximately 1.03% of Oruka Therapeutics worth $6,995,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ORKA. Vanguard Group Inc. boosted its stake in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after buying an additional 1,572,853 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Oruka Therapeutics by 374.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after purchasing an additional 1,047,245 shares during the last quarter. FMR LLC lifted its stake in Oruka Therapeutics by 17.7% in the fourth quarter. FMR LLC now owns 5,512,300 shares of the company's stock valued at $106,883,000 after purchasing an additional 830,000 shares during the last quarter. Braidwell LP lifted its stake in Oruka Therapeutics by 122.5% in the fourth quarter. Braidwell LP now owns 1,147,676 shares of the company's stock valued at $22,253,000 after purchasing an additional 631,950 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Oruka Therapeutics by 259.7% in the fourth quarter. Janus Henderson Group PLC now owns 849,410 shares of the company's stock valued at $16,415,000 after purchasing an additional 613,294 shares during the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $10.31 on Tuesday. The company's fifty day simple moving average is $9.84 and its two-hundred day simple moving average is $14.56. Oruka Therapeutics, Inc. has a 1 year low of $5.49 and a 1 year high of $31.13. The stock has a market capitalization of $386.02 million, a price-to-earnings ratio of -1.65 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Equities research analysts anticipate that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research assumed coverage on Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, May 15th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.